Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Report Links Nuplazid to High Number of Deaths

Shares of Acadia Pharmaceuticals were down following a CNN report that raises concerns over a number of deaths and adverse events linked to the company’s Parkinson’s disease drug Nuplazid.

Read More »

Roche shares drop after deaths of patients taking Hemlibra

Roche’s shares dropped after the Swiss drugmaker told U.S.-based hemophilia advocacy groups that five patients treated with its medicine Hemlibra had died, while maintaining that the therapy was not the cause of the deaths.

Read More »

Tokyo court rejects Shire claim against Roche hemophilia drug

A Tokyo court ruled that Shire’s claim against Swiss drugmaker Roche’s new Hemlibra hemophilia medicine should be dismissed, Roche’s Japanese subsidiary Chugai said.

Read More »

GSK wins new reprieve as Hikma’s generic Advair delayed again

The FDA insisted Hikma conduct a further clinical study evaluating its generic version of GlaxoSmithKline’d blockbuster lung drug.

Read More »

Regeneron/Sanofi heart drug succeeds in major trial

A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study.

Read More »

Biogen, AbbVie Voluntarily Pull Multiple Sclerosis Drug Off The Market

Biogen and AbbVie voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.

Read More »

U.S. health officials reverse stance on flu vaccine

An advisory committee of the U.S. CDC recommended the use of AstraZeneca’s FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

Read More »

Special Feature – Value of Medicines: The value equation

As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.

Read More »

Value of Medicines: PBM waste makes valuable drugs valueless

On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.

Read More »

U.S. healthcare spending to climb 5.3 percent in 2018: agency

United States health spending is projected to rise 5.3 percent in 2018, reflecting rising prices of medical goods and services and higher Medicaid costs.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom